Navigation Links
New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearch's cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
Date:7/19/2010

PARIS, July 19 /PRNewswire-FirstCall/ -- Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS)(1). The study demonstrated Cellectis bioresearch's technology to be faster, more reliable and efficient in deriving cell-based assays for HTS studies than classical methods. The study has been published online by Journal of Biomolecular Screening http://jbx.sagepub.com/cgi/content/abstract/1087057110375115v1.

The development of cell-based assays for HTS approaches is important to screen molecules on pharmaceutical targets and often requires the generation of stable cell lines. However, these cell lines are essentially created by random integration of a gene of interest (GOI) with no control over the level and stability of gene expression. In this study, scientists from the Servier Research institute used Cellectis bioresearch's cellular Genome Positioning System, or cGPS®, in CHO-K1 cells, to accomplish targeted integration of different GOIs. Five different GOIs representing 3 major drug target classes were stably integrated at the same locus in cGPS® CHO-K1 cells. Characterization of the targeted clones revealed that the cGPS® CHO-K1 system was more rapid (2-week protocol), efficient (all selected clones expressed the GOI), reproducible (GOI expression level variation of 12% maximum), and stable over time (no change in GOI expression after 23 weeks of culture) than classical random integration.

"Achieving a physiological level of expression compatible with the relevant functional assay is important in testing pharmaceutical targets", explained Jean Boutin, Director of the Molecular and Cellular Pharmacology Division of the SERVIER Research Institute. "We found that proteins expressed in the cGPS® CHO-K1 cells are biologically active and have enzymatic constants, localization and function close to the published values of their wild-type endogenous counterparts. This fast and robust method opens the door for creating large collections of cell lines expressing therapeutically relevant GOIs, enhancing the productivity of HTS".

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with ready-to-use research tools for genome customization.  These tools, based on meganucleases, enable the customization of cells with optimized features for drug discovery, protein production and gene function study.

More information at www.cellectis-bioresearch.com

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at www.cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) JP Cabaniols et al. Meganuclease-driven targeted integration in CHO-K1 cells fort he fast generation of HTS compatible cell-based assays. Journal of Biomolecular Screening 2010, doi:10.1177/1087057110375115


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
2. Worlds Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
3. Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology
4. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
5. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
6. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
7. Drug Study Shows Improvement in Major Orthopedic Surgery Care
8. Enrollment Underway in CLARITY-AF Study to Compare Efficacy, Safety and Efficiency of Two Catheter Ablation Technologies
9. Nile Therapeutics Completes Dosing of Phase II Study
10. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
11. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology:
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
Breaking Medicine News(10 mins):